EMD Serono Media Center
Latest NewsView all news
The U.S. Healthcare business plans to move to 200 Pier 4 Boulevard in Boston’s Seaport district in summer 2024.
Collaboration to develop, manufacture and commercialize next-generation selective PARP1 inhibitor HRS-1167, with option to develop, manufacture and commercialize Claudin18.2 antibody-drug conjugate SHR-A1904.
28 abstracts featuring the latest research on the company’s oncology portfolio addressing unmet needs across bladder, head and neck, lung, colorectal and other cancers, will be presented.
The Media Center is a service for journalists, bloggers and online multipliers that allows you to access news about EMD Serono.